Korro Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Core Insights - Korro Bio, Inc. is focused on developing RNA editing-based genetic medicines for rare and prevalent diseases, reporting significant progress in its clinical development and financial position for the year ending December 31, 2025 [1][2]. Financial Performance - As of December 31, 2025, Korro reported cash, cash equivalents, and marketable securities of $85.2 million, a decrease from $163.1 million in 2024, but expects funding to last into the second half of 2028 due to a recent $85 million private placement [6][23]. - Collaboration revenue increased to $6.4 million in 2025 from $2.3 million in 2024, attributed to a full year of collaboration with Novo Nordisk [7]. - Research and Development (R&D) expenses rose to $65.6 million in 2025 from $63.6 million in 2024, driven by increased costs related to KRRO-121 [8]. - General and Administrative (G&A) expenses decreased to $28.2 million in 2025 from $30.5 million in 2024, mainly due to lower professional fees [9]. - The net loss for 2025 was $117.3 million, compared to $83.6 million in 2024, primarily due to non-cash impairment charges [13][21]. Product Development - Korro nominated KRRO-121 as a development candidate for treating hyperammonemia in patients with urea cycle disorders (UCDs) and hepatic encephalopathy (HE), targeting a market opportunity exceeding $1 billion [4][5]. - KRRO-121 aims to stabilize glutamine synthase (GS) RNA, enhancing ammonia clearance in the liver and offering a more convenient subcutaneous delivery method compared to current therapies [5][16]. - The company is on track to nominate a development candidate for its GalNAc-conjugated oligonucleotide for alpha-1 antitrypsin deficiency (AATD) in the second quarter of 2026 [4][11]. Strategic Initiatives - Korro hosted a virtual analyst day to discuss the unmet medical needs in hyperammonemia and the scientific rationale for KRRO-121 [11]. - The company is advancing its GalNAc-conjugated oligonucleotide program, achieving over 90% in vivo RNA editing, indicating high therapeutic potential [11]. - Upcoming milestones include regulatory filing for KRRO-121 in the second half of 2026 and the nomination of a third GalNAc-conjugated program [11].